$ACHV News
Last published 1d ago
- 1d agoACHVACHIEVE LIFE SCIENCES, INC. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 1d agoACHVQUITAchieveRx Reports Third Quarter 2026 Financial Results and Provides Business UpdatesGlobeNewswire
- 2d agoACHVAchieve Life Sciences Becomes AchieveRx, The Quit Company, and Will Trade Under the Ticker QUITGlobeNewswireSEATTLE and VANCOUVER, British Columbia, Nov. 09, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV) today announced that it has rebranded and will now be doing business as AchieveRx™, The Quit
- 1w agoACHVAchieve Life Sciences Announces Granting of New Hire Inducement AwardsGlobeNewswireSEATTLE and VANCOUVER, British Columbia, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and
- 3w agoACHVAchieve Life Sciences Presents 52-Week Cytisinicline Results for Smoking and Vaping Cessation at CHEST 2026GlobeNewswireNearly one in three adults who were still smoking or vaping after a prior ORCA trial had quit at the end of a year of cytisinicline treatment, with quit rates rising through the year Among the participants new to
- 4w agoLSTATARSACHVLisata Therapeutics Appoints Jeff Farrow to Board of DirectorsGlobeNewswireLIBERTY CORNER, N.J., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (NASDAQ:LSTA) ("Lisata" or the "Company") today announced the appointment of Jeffrey Farrow to its Board of Directors,
- 1mo agoACHVAchieve Life Sciences Appoints Kaitlyn Tuson as Senior Vice President, Marketing and CommunicationsGlobeNewswireSEATTLE and VANCOUVER, British Columbia, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve and the Company) (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global
- 1mo agoACHVAchieve Life Sciences Announces Granting of New Hire Inducement AwardsGlobeNewswireSEATTLE and VANCOUVER, British Columbia, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve or the Company) (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global
- 2mo agoACHVAchieve Life Sciences Announced Granting of New Hire Inducement AwardsGlobeNewswireSEATTLE and VANCOUVER, British Columbia, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and
- 3mo agoACHVAchieve Life Sciences Reports Second Quarter 2026 Financial Results and Provides Business UpdatesGlobeNewswireClosed a private placement of up to $354 million, with $180 million upfront and up to $174 million from warrants exercisable prior to and up to 20 trading days following FDA approval Strengthened organization with new
- 3mo agoACHVAchieve Life Sciences Appoints Ronald Dadino and Gloria Cosgrove to Lead CMC, Supply Chain, and QualityGlobeNewswireSEATTLE and VANCOUVER, British Columbia, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve or the Company) (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global
- 3mo agoACHVAchieve Life Sciences Announced Granting of New Hire Inducement AwardsGlobeNewswireSEATTLE and VANCOUVER, British Columbia, July 31, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and
- 4mo agoACHVAchieve Life Sciences Joins Russell 2000® IndexGlobeNewswireSEATTLE and VANCOUVER, British Columbia, June 29, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve or the Company) (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global
- 4mo agoACHVAchieve Life Sciences Receives Complete Response Letter from FDA for Cytisinicline NDAGlobeNewswireCRL Cites Deficiencies at Third-Party Manufacturing Facility No Efficacy or Clinical Safety Deficiencies Identified SEATTLE and VANCOUVER, British Columbia, June 22, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences,
- 5mo agoACHVMANETARSAchieve Life Sciences Appoints Jeffrey Farrow and Reid Waldman, MD to Board of DirectorsGlobeNewswireSEATTLE and VANCOUVER, British Columbia, June 02, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. ("Achieve" or the "Company") (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global
- 5mo agoACHVAchieve Life Sciences Presents Safety Data from 52 Weeks of Continuous Cytisinicline TreatmentGlobeNewswireORCA-OL data complete the clinical evidence package supporting the cytisinicline smoking cessation NDA No new safety signals identified by the independent Data Safety Monitoring Committee over 52 weeks of continuous
- 6mo agoACHVEWTXORKAAchieve Life Sciences Strengthens Board and Commercial Leadership with Three Senior Appointments from Team Previously at Verona PharmaGlobeNewswireSEATTLE and VANCOUVER, British Columbia, May 12, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Achieve and the Company) (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global
- 6mo agoACHVAchieve Life Sciences Reports First Quarter 2026 Financial Results and Provides Business UpdatesGlobeNewswireClosed Private Placement of Up to $354 Million, Including $180 Million Upfront and $174 Million in Milestone-Driven Warrants Appoints New CEO and Expands Board of Directors Advances U.S.-based Manufacturing Transition
- 6mo agoACHVAchieve Life Sciences to Announce First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 12, 2026GlobeNewswireSEATTLE and VANCOUVER, British Columbia, May 05, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization
- 6mo agoACHVAchieve Life Sciences Announces Appointment of Andrew D. Goldberg, MD, as Chief Executive Officer and to the Board of DirectorsGlobeNewswireAchieve Names Two New Exemplary Healthcare Leaders to its Board of Directors New Leadership and Financing, up to $354 Million ($180 Million Upfront and $174 Million Dependent on the Exercise of Milestone Warrants),
- 6mo agoACHVAchieve Life Sciences Announces Up to $354 Million Private PlacementGlobeNewswire$180 Million Financing Upfront with Up to an Additional $174 Million from Warrants Exercisable Within 20 Days of FDA Approval Transaction led by Frazier Life Sciences, TPG Life Sciences Innovations, venBio Partners,
- 7mo agoACHVAchieve Life Sciences Announces Operational Progress Including Completion of Technology Transfer to Adare Pharma SolutionsGlobeNewswireAdare Partnership Provides Supply Chain Redundancy and U.S.-based Manufacturing Capability Company Reiterates Guidance - If Approved, Cytisinicline Commercial Launch Expected in First Half of 2027 SEATTLE and
- 7mo agoACHVAchieve Life Sciences Announces Publication in Nicotine & Tobacco Research Linking Cytisinicline's Receptor Selectivity to Low Nausea Rates and Favorable TolerabilityGlobeNewswireSEATTLE and VANCOUVER, British Columbia, March 26, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and
- 7mo agoACHVAchieve Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdatesGlobeNewswireAchieve also Announces Partnership with U.S.-based Adare Pharma Solutions for Cytisinicline Manufacturing Conference Call Scheduled for 8:30 AM EDT Today, March 24, 2026 SEATTLE and VANCOUVER, British Columbia, March
- 8mo agoACHVAchieve Life Sciences Presents Data at SRNT Demonstrating Successful Cessation in Smokers with Extensive Prior Treatment Exposure; and on Participant Experience in the ORCA-OL StudyGlobeNewswireA pooled Phase 3 analysis of more than 1,600 people who smoke showed high quit rates; including among those who had previously not succeeded with other smoking cessation medications and regardless of the number of prior
- 9mo agoACHVAchieve Life Sciences Announced Granting of New Hire Inducement AwardsGlobeNewswireSEATTLE and VANCOUVER, British Columbia, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and
- 10mo agoACHVAchieve Life Sciences Confirms Promotion of Dr. Mark Rubinstein to Chief Medical OfficerGlobeNewswireSEATTLE and VANCOUVER, British Columbia, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and
- 10mo agoACHVAchieve Life Sciences to Host Meetings During the J.P. Morgan Healthcare Conference WeekPR NewswireAchieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of...
- 11mo agoACHVAchieve Life Sciences Announced Granting of New Hire Inducement AwardsGlobeNewswireSEATTLE and VANCOUVER, British Columbia, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and
- 1y agoACHVAchieve Life Sciences Reports Third Quarter 2025 Financial Results; Provides Updates on Cytisinicline ProgramGlobeNewswireOne of Only Nine Therapies Chosen for the Inaugural FDA Commissioner's National Priority Voucher for E-cigarette or Vaping CessationConference Call Scheduled for 8:30 AM EST Today, November 6, 2025 SEATTLE and
- 1y agoACHVAchieve Life Sciences Meets Key Milestones Advancing Cytisinicline NDA for Smoking CessationGlobeNewswire120-Day Safety Update Submitted to FDA ORCA-OL Long-Term Safety Trial Successfully ConcludedDSMC Completes Final Review of Cytisinicline, Finds No Drug Safety Concerns SEATTLE and VANCOUVER, British Columbia, Nov. 03,
- 1y agoACHVAchieve Life Sciences to Announce Third Quarter Financial Results and Host Conference Call and Webcast on November 6, 2025GlobeNewswireSEATTLE and VANCOUVER, British Columbia, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and
- 1y agoACHVAchieve Life Sciences Appoints Erik Atkisson as Chief Legal OfficerGlobeNewswireSEATTLE and VANCOUVER, British Columbia, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and
- 1y agoACHVAchieve Life Sciences Receives FDA Commissioner's National Priority Voucher for Cytisinicline for Treatment of Nicotine Dependence for E-cigarette or Vaping CessationGlobeNewswirePotential First-in-Class Treatment for Nicotine E-cigarette or Vaping Cessation Receives Unprecedented Expedited Review Pathway One of Only Nine Therapies Chosen for the FDA's Inaugural National Priority Voucher Program
- 1y agoACHVAchieve Life Sciences Announces Granting of New Hire Inducement AwardsGlobeNewswireSEATTLE and VANCOUVER, British Columbia, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and
- 1y agoACHVAchieve Life Sciences Announces Publication in Thorax of Data Demonstrating Cytisinicline's Potential Efficacy and Tolerability for Smoking Cessation in Individuals with COPDGlobeNewswireSEATTLE and VANCOUVER, British Columbia, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and
- 1y agoACHVAchieve Life Sciences Promotes Craig Donnelly to Chief Operations OfficerGlobeNewswireSEATTLE and VANCOUVER, British Columbia, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and
- 1y agoACHVAchieve Life Sciences Names Dr. Mark Rubinstein Interim Chief Medical OfficerGlobeNewswireSEATTLE and VANCOUVER, British Columbia, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and
- 1y agoACHVAchieve Life Sciences Announces FDA Acceptance of Cytisinicline New Drug Application for Treatment of Nicotine Dependence for Smoking CessationGlobeNewswireFiling based on pivotal Phase 3 ORCA-2 and ORCA-3 clinical trials demonstrating statistically significant and clinically meaningful smoking cessation FDA acceptance starts the review process and sets timing for
- 1y agoACHVAchieve Life Sciences Announces Participation at Upcoming Investor ConferencesGlobeNewswireSEATTLE and VANCOUVER, British Columbia, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and
- 1y agoACHVAchieve Life Sciences, Inc. (ACHV) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoACHVAchieve Life Sciences Reports Second Quarter 2025 Financial Results; Provides Updates on Cytisinicline ProgramGlobeNewswireSEATTLE and VANCOUVER, British Columbia, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and
- 1y agoACHVAchieve Life Sciences to Participate in the BTIG Virtual Biotechnology ConferenceGlobeNewswireSEATTLE and VANCOUVER, British Columbia, July 29, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and
- 1y agoACHVAchieve Life Sciences to Announce Second Quarter Financial Results and Host Conference Call and Webcast on August 7, 2025GlobeNewswireSEATTLE and VANCOUVER, British Columbia, July 24, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and
- 1y agoACHVAchieve Life Sciences Announces Closing of Public Offering of Common Stock and Partial Exercise of Underwriters' Option to Purchase Additional SecuritiesGlobeNewswireSEATTLE and VANCOUVER, British Columbia, June 30, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and
- 1y agoACHVAchieve Life Sciences Announces Pricing of $45.0 Million Underwritten Public OfferingGlobeNewswireSEATTLE and VANCOUVER, British Columbia, June 26, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and
- 1y agoACHVAchieve Life Sciences Announces Proposed Underwritten Public OfferingGlobeNewswireSEATTLE and VANCOUVER, British Columbia, June 26, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and
- 1y agoACHVOMCAchieve Life Sciences Announces Partnership with Omnicom to Execute Integrated, Data-Driven Launch of the First Potential New Treatment for Nicotine Dependence in Nearly Two DecadesGlobeNewswireOmnicom cross-agency collaboration to drive technology-led, innovative launch strategy Partnership brings together promising science, top-tier talent, and advanced technologies to enable a faster, smarter, and more
- 1y agoACHVAchieve Life Sciences Announces Submission of NDA to FDA for Cytisinicline as a Treatment of Nicotine Dependence for Smoking CessationGlobeNewswireSmoking, the leading cause of preventable death and disease, continues to affect nearly 29 million adults in the U.S. alone If approved, cytisinicline will be the first new FDA-approved pharmacotherapy option for
- 1y agoACHVAchieve Life Sciences to Present at the Jefferies Global Healthcare ConferenceGlobeNewswireSEATTLE and VANCOUVER, British Columbia, May 28, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization